Production ability of 177Lu from natural lutetium target on the Da Lat nuclear reactor
Main Article Content
Abstract
SUMMARY
177Lu is presently being considered as a potential radionuclide, for use in in-vivo targeted radiotherapy, owing to its favorable nuclear decay characteristics. This paper presents some research fi ndings on the ability to produce 177Lu on the IVV-9 research reactor with thermal neutron fl ux of 1.8×1013.cm-2.s-1 at the Nuclear Research
Institute to produce this radioactive isotope. Our products have specifi c activity of 17.7 mCi/mg Lu, radionuclide and radiochemical purities more than 99.9% of total radioactivity. Immediate products are used for the initial basic research of labeling capabilities with DOTATATE, and especially studying on the possibility preparing 177Lu-EDTMP used to treat pain palliation caused by bone metastases.
Article Details
Keywords
production of Lu-177, nuclear reactor IVV-9,, 177Lu-EDTMP, pain palliation.
References
1. IAEA-TECDOC-1340, Manual for reactor produced radioisotopes, January 2003.
2. Pillai MRA, Chakeraborty, Das T, Venkatesh M, Ramamoorthy N (2003) Production logistics of 177Lu for radionuclide therapy. Applied Radiation and Isotopes, 59:109-118.
3. K. Hashimoto, H. Matsuoka, S. Uchida, Production of no-carrier-added 177Lu via the 176Yb(n, )177Yb, 177Lu process, Journal of Radioanalytical and Nuclear Chemistry, Vol. 255, No. 3 (2003) 575–579.
4. IAEA. Quality assurance manual for radiopharmaceuticals – 2002.
5. Quality of Radiopharmaceuticals. Specifi cations and test Procedures, Australian Radiation Laboratory, Department of Community Services and Health, Second
Edition. 1990.
6. IAEA, Preparation and Control of Radiopharmaceuticals in hospitals, K. Kristensen, IAEA Technical Report series No. 194, Vienna, (1979).
7. Recommendations of the International Commission on Radiology Protection. ICRP Publication No. 60, 1991.
8. Report on the 1st Research Coodination Meeting on “Development of Therapeutic Radiopharma-ceuticals Based on 177Lu for Radionuclide Therapy” 4 to 8 December 2006 IAEA Headquarters,Vienna, Austria